New Products
A survey of new Rx, new generic, and new OTC products
Key Points
RX CARE
New drugs
Orsythia Tablets (levonorgestrel and ethinyl estradiol 0.1 mg/0.02 mg) from Qualitest Pharmaceuticals have been approved for the prevention of pregnancy in women who elect to use oral contraceptives.( http://www.qualitestrx.com/ / 800-444-4011)
Regency Therapeutics and Daiichi Sankyo have made available Sprix Nasal Spray (ketorolac tromethamine) for short-term (up to 5 days) management of moderate-to-moderately-severe pain that requires an opioid analgesic. Bottle contains 8 sprays, delivering 15.75 mg in each 100 µL of ketorolac tromethamine. ( http://ww.sprix.com/ / 888-354-4855)
New indications
FDA approved Novartis' Afinitor (everolimus tablets) to treat progressive neuroendocrine tumors of pancreatic origin in patients with unresectable, locally advanced, or metastatic disease. Afinitor, an mTOR kinase inhibitor, is already indicated for treatment in some circumstances of advanced renal cell carcinoma and subependymal giant cell astrocytoma associated with tuberous sclerosis. ( http://www.afinitor.com/ / 888-NOW-NOVA)
AstraZeneca's Nexium IV (esomeprazole sodium for injection) is approved for use in children >1 month of age for short-term treatment of gastroesophageal reflux disease (GERD) with erosive esophagitis when oral therapy is not appropriate. Nexium IV is already indicated for use in adults ≥18 years old. ( http://www.nexiumtouchpoints.com/ / 800-236-9933)
